This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 2003 Sep 6;362(9386):754-5.

doi: 10.1016/S0140-6736(03)14294-8.

Candesartan and heart failure: the allure of CHARM

Harvey D White¹

Affiliations

PMID: 13678864
DOI: 10.1016/S0140-6736(03)14294-8

Comparative Study

Candesartan and heart failure: the allure of CHARM

Harvey D White. Lancet. 2003.

. 2003 Sep 6;362(9386):754-5.

doi: 10.1016/S0140-6736(03)14294-8.

Author

Harvey D White¹

Affiliation

¹ Cardiology Department, Green Lane Hospital, Auckland, New Zealand. harveyw@adhb.govt.nz

PMID: 13678864
DOI: 10.1016/S0140-6736(03)14294-8

No abstract available

PubMed Disclaimer

Comment in

The CHARM programme.
Penston J. Penston J. Lancet. 2003 Nov 15;362(9396):1678; author reply 1678-9. doi: 10.1016/S0140-6736(03)14813-1. Lancet. 2003. PMID: 14630459 No abstract available.

Comment on

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Pfeffer MA, et al. Lancet. 2003 Sep 6;362(9386):759-66. doi: 10.1016/s0140-6736(03)14282-1. Lancet. 2003. PMID: 13678868 Clinical Trial.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. McMurray JJ, et al. Lancet. 2003 Sep 6;362(9386):767-71. doi: 10.1016/S0140-6736(03)14283-3. Lancet. 2003. PMID: 13678869 Clinical Trial.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Granger CB, et al. Lancet. 2003 Sep 6;362(9386):772-6. doi: 10.1016/S0140-6736(03)14284-5. Lancet. 2003. PMID: 13678870 Clinical Trial.
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Yusuf S, et al. Lancet. 2003 Sep 6;362(9386):777-81. doi: 10.1016/S0140-6736(03)14285-7. Lancet. 2003. PMID: 13678871 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information